Cytotrienin A

Cytotrienin A is a secondary metabolite isolated from Streptomyces sp. RK95-74, a bacterium found in soil in Japan in 1997[1]. It belongs to the ansamycin class of compounds, characterized by a macrocyclic lactam structure with a twenty-one carbon ring system featuring an E,E,E-triene and an unusual aminocyclopropane carboxylic acid side chain[1]. The structure of cytotrienin A includes four stereocenters, three of which are contiguous, and its absolute stereochemistry has been determined to be (+)-Cytotrienin A[1].

Biological Activity

Cytotrienin A has been found to induce apoptosis (programmed cell death) in HL-60 cells, a human leukemia cell line, and inhibit translation in eukaryotes by targeting eukaryotic elongation factor 1A (eEF1A)[1]. This inhibition of translation can lead to a decrease in the production of anti-apoptotic proteins, making the tumor more susceptible to apoptosis and reducing its drug resistance[1]. Additionally, cytotrienin A has been shown to inhibit the formation of tubes by human umbilical vein endothelial cells (HUVECs), indicating an anti-angiogenic effect[1].

Mechanism of Action

The apoptosis induced by cytotrienin A is thought to involve the activation of several protein kinases, including c-Jun N-terminal Kinase (JNK), p38 mitogen-activated protein kinase (MAPK), and p36 myelin basic protein (MBP) kinase[1]. The activation of these kinases can lead to the proteolytic activation of MST/Krs proteins by caspase-3, which is a key step in the apoptosis pathway[1]. Cytotrienin A has also been shown to inhibit the expression of intercellular adhesion molecule-1 (ICAM-1) in A549 cells, a human lung carcinoma cell line[1].

Synthesis and Potential Applications

The asymmetric total synthesis of (+)-cytotrienin A has been reported, employing a novel approach involving the late-stage installation of a key fragment[2]. This synthesis is important for the potential development of cytotrienin A as an anticancer agent, particularly for the treatment of blood cancers, where it has shown greater effectiveness against leukemic cell lines[1]. The median effective dose of cytotrienin A to induce apoptosis in HL-60 cells is 7.7 nM, and it has been shown to have greater growth inhibitory activity at low concentrations[1].

In summary, cytotrienin A is a potent apoptosis inducer and translation inhibitor with potential applications in the treatment of cancer, particularly blood cancers. Its unique structure and mechanism of action make it an interesting target for further research and development.

Citations:

[1] https://en.wikipedia.org/wiki/Cytotrienin_A

[2] https://onlinelibrary.wiley.com/doi/full/10.1002/anie.202303140

[3] https://pubmed.ncbi.nlm.nih.gov/21663740/

[4] https://pubchem.ncbi.nlm.nih.gov/compound/Cytotrienin-A

[5] https://www.sciencedirect.com/science/article/abs/pii/S0014299911006765